The market for cardiac surgery devices was valued at $2 billion in 2010. That includes surgery related to heart valve problems that require mitral valve repair to treat patients who suffer mitral regurgitation. One Minnesota company wants to take a portion of the mitral valve repair market by commercializing a minimally invasive cardiac surgery device […]
The first patient in NeoChord Inc.'s European clinical trial has been implanted with an artificial chord to treat his faulty heart valve.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
NeoChord Inc. in Minnetonka, Minn., has raised at least $2.8 million to help it continue to develop a novel way of enabling surgeons to repair bad mitral valves in patients' hearts.